急性髓系白血病108例免疫表型特征与临床预后分析  

Analysis of immunophenotyping characteristics and clinical prognosis of 108 patients with acute myeloid leukaemia

作　　者：马瑞霞[1] 叶芳[1] 李国霞[2] 任方刚[2] 王宏伟[2] 魏百合[1] 何玉梅[1] 甄祯[1] 周文峰[1] 乔振华[1] 

机构地区：[1]山西医科大学第二医院血液科,太原030001 [2]山西医科大学第二医院血液科实验室,太原030001

出　　处：《中国药物与临床》2013年第2期147-150,共4页Chinese Remedies & Clinics

基　　金：山西省归国留学基金[晋留管办发(2009)9号106];山西省人事厅择优资助项目[晋财社(2011)172号];山西省国际科技合作项目(2012081044-1)

摘　　要：目的评价免疫分型在判断急性髓系白血病(AML)预后中的作用。方法采用流式细胞术对108例初发AML患者骨髓进行免疫表型检测。结果①AML患者中髓系抗原表达率以CD33(96.3%)、CD13(88.0%)、髓过氧化物酶(MPO)(88.0%)最常见,造血祖/干细胞抗原表达以CD38最常见,为95.4%;②有52.8%(57/108)AML患者同时伴有淋巴系抗原表达,主要为CD19、CD7、CD4,表达率分别为23.1%、21.3%、17.6%;③高、中、低危3组AML患者淋巴系抗原表达率进行比较,发现CD4、CD7低危组低于中危组和高危组(P均<0.01),而CD19的表达率则相反,低危组高于中、高危组(P均<0.05)。结论免疫分型在诊断AML及判断预后中起重要作用。Objective To evaluate the impact of immunophenotyping on diagnosis and prognosis of acute myeloid leukaemia （AML）. Methods Flow cytometry （FCM） was used to detect the immunophenotype of bone marrow in 108 patients with primary AML. Results （1）Of AML patients, the expression rates of antigens were mainly CD33 （96.3%）, CD13 （88.0%） and MPO （88.0%） in bone mallow. Notably, CD38 was most commonly seen in hematopoietic stem / progenitor of antigen, being 95.4%. （2）There were 52.8% （57/108） AML patients had expressions of lymphoid-associated antigen, mainly CD19 （23.1%）, CD7 （21.3%） and CD4 （17.6%）. （3）Among 3 groups of AML patients in high, moderate and low risk degrees, the lymphoid antigen expressions of CD4 and CD7 in low risk group were lower than those in moderate and high risk group （both P〈0.01）, which was on contrary to the expression of CD19 （both P〈0.05）. Conclusion The immunophenotyping played an important role in diagnosis and prognosis of AML.

关 键 词：白血病 髓样 预后 抗原分化 免疫分型 

分 类 号：R733.71[医药卫生—肿瘤]